Trade Merrimack Pharmaceuticals, Inc. - MACK CFD
Add to favourite- Summary
- Historical Data
- Events
- Ownership
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 12.72 |
| Open* | 12.72 |
| 1-Year Change* | 7.71% |
| Day's Range* | 12.64 - 12.74 |
| 52 wk Range | N/A |
| Average Volume (10 days) | N/A |
| Average Volume (3 months) | N/A |
| Market Cap | N/A |
| P/E Ratio | N/A |
| Shares Outstanding | N/A |
| Revenue | N/A |
| EPS | N/A |
| Dividend (Yield %) | N/A |
| Beta | N/A |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 29, 2023 | 12.64 | -0.08 | -0.63% | 12.72 | 12.74 | 12.58 |
| Nov 28, 2023 | 12.72 | 0.02 | 0.16% | 12.70 | 12.76 | 12.70 |
| Nov 27, 2023 | 12.86 | 0.10 | 0.78% | 12.76 | 12.86 | 12.75 |
| Nov 24, 2023 | 12.76 | 0.00 | 0.00% | 12.76 | 12.89 | 12.76 |
| Nov 22, 2023 | 12.74 | 0.45 | 3.66% | 12.29 | 12.87 | 12.29 |
| Nov 21, 2023 | 12.72 | 0.19 | 1.52% | 12.53 | 12.82 | 12.53 |
| Nov 20, 2023 | 12.71 | 0.20 | 1.60% | 12.51 | 12.82 | 12.51 |
| Nov 17, 2023 | 12.78 | 0.28 | 2.24% | 12.50 | 12.79 | 12.50 |
| Nov 16, 2023 | 12.73 | 0.26 | 2.09% | 12.47 | 12.75 | 12.47 |
| Nov 15, 2023 | 12.68 | 0.37 | 3.01% | 12.31 | 12.74 | 12.31 |
| Nov 14, 2023 | 12.49 | 0.18 | 1.46% | 12.31 | 12.50 | 12.31 |
| Nov 13, 2023 | 12.37 | 0.23 | 1.89% | 12.14 | 12.37 | 12.14 |
| Nov 10, 2023 | 12.36 | 0.35 | 2.91% | 12.01 | 12.36 | 12.01 |
| Nov 9, 2023 | 12.16 | 0.11 | 0.91% | 12.05 | 12.17 | 12.05 |
| Nov 8, 2023 | 12.21 | 0.22 | 1.83% | 11.99 | 12.21 | 11.96 |
| Nov 7, 2023 | 11.98 | -0.28 | -2.28% | 12.26 | 12.34 | 11.96 |
| Nov 6, 2023 | 12.43 | 0.17 | 1.39% | 12.26 | 12.49 | 12.20 |
| Nov 3, 2023 | 12.41 | 0.24 | 1.97% | 12.17 | 12.45 | 12.17 |
| Nov 2, 2023 | 12.31 | 0.14 | 1.15% | 12.17 | 12.31 | 12.15 |
| Nov 1, 2023 | 12.26 | 0.15 | 1.24% | 12.11 | 12.29 | 12.11 |
Merrimack Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Merrimack Pharmaceuticals, Inc. Company profile
About Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $2M. Higher net loss reflects Gain on sale of assets decrease of 93% to $144K (income), Interest income decrease of 61% to $19K (income), Other income (expense), net decrease from $18K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.15.
Equity composition
Common Stock $0.01 Par, 02/12, 200M auth., 94,756,679 issd. Insiders own 9.59%. IPO:TBA
News
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com